We have collected information about Biodelivery Sciences Bema for you. Follow the links to find out details on Biodelivery Sciences Bema.
https://bdsi.com/BEMA-Technology/
The BEMA technology may also be developed with other active drugs, particularly in conditions where rapid delivery of drug is important, oral dosing is not optimal, or where intravenous line or injections are unavailable or not practical. BDSI owns the worldwide rights to the BEMA drug delivery technology.
BioDelivery Sciences (BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ...
http://ir.bdsi.com/investor-resources/investor-contact
The Investor Relations website contains information about BioDelivery Sciences International, Inc.'s business for stockholders, potential investors, and financial analysts.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
http://www.businesswire.com/news/home/20101020005551/en/BioDelivery-Sciences-Meda-Announce-European-Approval-BEMA
Oct 20, 2010 · BioDelivery Sciences and Meda Announce the Approval of BEMA Fentanyl in the European Union. The product, already approved in the U.S. and Canada as ON
https://www.linkedin.com/company/biodeliverysciences
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is ...
https://www.glassdoor.com/Overview/Working-at-BioDelivery-Sciences-International-EI_IE13730.11,45.htm
Aug 13, 2018 · Glassdoor gives you an inside look at what it's like to work at BioDelivery Sciences International, including salaries, reviews, office photos, and more. This is the BioDelivery Sciences International company profile. All content is posted anonymously by employees working at BioDelivery Sciences International.5/5(6)
https://bdsi.gcs-web.com/news-releases/news-release-details/biodelivery-sciences-report-fourth-quarter-and-full-year-2019
About BioDelivery Sciences International, Inc. BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ®) technology to develop and commercialize, either on its own ...
http://www.businesswire.com/news/home/20101209005255/en/BioDelivery-Sciences-Announces-Enrollment-Patient-Phase-3
BioDelivery Sciences Announces Enrollment of the First Patient in the Phase 3 BEMA Buprenorphine Clinical Program Phase 3 data anticipated in third-quarter of 2011 December 09, 2010 07:00 AM ...
https://www.marketwatch.com/press-release/biodelivery-sciences-announces-bema-buprenorphine-nda-submission-on-track-following-pre-nda-meeting-with-fda-2014-08-12
Aug 12, 2014 · BioDelivery Sciences International, Inc. BDSI, -3.62% is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is …
Searching for Biodelivery Sciences Bema?
You can just click the links above. The data is collected for you.
